Immunotherapy Checkpoint Patents

Immunotherapy checkpoint patents cover anti-PD-1 and anti-PD-L1 antibody composition and binding domain innovations; CTLA-4 blockade mechanism and combination therapy innovations; biomarker-guided patient selection innovations; and combination checkpoint blockade and CAR-T integration innovations — with IP held by large pharma, academic medical centers, and immuno-oncology biotechs: MAJOR IMMUNOTHERAPY CHECKPOINT PATENT HOLDERS: BRISTOL MYERS SQUIBB: 2,000+; specific Opdivo/Yervoy innovations (specific specific Opdivo nivolumab anti-PD-1: specific specific fully human IgG4 antibody from specific specific S228P stabilizing mutation Fc from specific specific binds PD-1 blocks PD-L1 PD-L2 from specific specific 2 mg/kg Q3W or 240 mg Q2W or 480 mg Q4W from specific specific NSCLC melanoma HNSCC RCC HCC from specific specific FDA approval December 2014 melanoma from specific specific 1-year OS 72.9% vs. 42.1% dacarbazine CheckMate 066 from specific specific Yervoy ipilimumab anti-CTLA-4: specific specific fully human IgG1 from specific specific 3 mg/kg Q3W ×4 melanoma from specific specific OS 11.2 months vs. 6.4 gp100 CheckMate 001 from specific specific FDA March 2011 first checkpoint inhibitor from specific specific 10 mg/kg adjuvant FDA 2015 from specific specific nivolumab+ipilimumab: specific specific 3+1 mg/kg Q3W×4 then N 3 mg/kg Q2W from specific specific 1 mg/kg nivo + 3 mg/kg ipi Q3W from specific specific 57.6% 5-year OS melanoma CheckMate 067); MERCK: 1,000+; specific Keytruda innovations (specific specific Keytruda pembrolizumab anti-PD-1: specific specific humanized IgG4 kappa from specific specific 200 mg Q3W fixed dose from specific specific pan-tumor TMB-H ≥10 mut/Mb 2020 FDA from specific specific MSI-H dMMR 2017 first tumor-agnostic from specific specific 40+ FDA approvals 2024 from specific specific melanoma NSCLC UC CRC HNSCC cervical from specific specific PD-L1 TPS ≥50% companion diagnostic 22C3); ASTRAZENECA: 500+; ROCHE/GENENTECH: 1,500+; PFIZER/MERCK KGaA: 300+.

Antibody Fc engineering and half-life extension innovations for checkpoint inhibitors; tumor biomarker companion diagnostic and patient selection innovations; and combination immunotherapy with chemotherapy radiation or targeted therapy innovations represent core checkpoint inhibitor patent domains: ANTIBODY ENGINEERING PATENTS: BMS; MERCK; AZ; REGENERON; ABBVIE; MACROGENICS: specific antibody innovations (specific specific IgG4 stabilization: specific specific S228P Fc mutation prevents Fab arm exchange from specific specific YTE M252Y/S254T/T256E half-life 3× from specific specific Fc silencing: specific specific L234A/L235A LALA null Fc effector from specific specific ADCC ablation for checkpoint from specific specific N297A or DAPA for aglycosylation from specific specific bispecific antibody: specific specific anti-PD-1×anti-CTLA-4 from specific specific Akeso cadonilimab AK104 from specific specific dual-checkpoint single molecule from specific specific anti-PD-L1×anti-TGFβ: specific specific Bintrafusp alfa M7824 from specific specific anti-PD-1×anti-LAG-3: specific specific relatlimab BMS-986016 from specific specific FDA RELATIVITY-047 melanoma 2022 from specific specific anti-PD-1×anti-TIGIT: specific specific tiragolumab SKYSCRAPER from specific specific antibody-drug conjugate ADC: specific specific DLL3 Rovalpituzumab SC-016 SCLC from specific specific PD-L1-directed ADC from specific specific pH-sensitive recycling FcRn binding from specific specific Xtend YTE technology MedImmune); BIOMARKER PATENTS: MERCK; ROCHE; VENTANA; DAKO; FOUNDATION MEDICINE: specific biomarker innovations (specific specific PD-L1 IHC: specific specific 22C3 Dako Agilent Keytruda from specific specific 28-8 Dako Nivolumab from specific specific SP142 Ventana Tecentriq from specific specific TPS tumor proportion score from specific specific CPS combined positive score from specific specific TPS ≥50% pembrolizumab NSCLC 1L from specific specific TMB tumor mutational burden: specific specific Foundation Medicine FoundationOne CDx from specific specific 10 mut/Mb threshold pan-tumor from specific specific FDA 2020 pembrolizumab TMB-H from specific specific MSI-H dMMR: specific specific MMR protein IHC MLH1 MSH2 MSH6 PMS2 from specific specific PCR microsatellite instability from specific specific FDA 2017 pembrolizumab first tumor-agnostic from specific specific COSMIC transcriptomics: specific specific tumor inflammation signature TIS from specific specific CD8+ T cell IFNγ cytotoxicity from specific specific CTLA-4 target expression); COMBINATION THERAPY PATENTS: BMS; MERCK; ROCHE; PFIZER; ELI LILLY: specific combination innovations (specific specific ICI+chemo: specific specific pembrolizumab+pemetrexed+carboplatin KEYNOTE-189 from specific specific OS 22.0 vs. 10.7 months HR 0.56 from specific specific ICI+VEGF: specific specific atezolizumab+bevacizumab+pemetrexed+carboplatin IMpower150 from specific specific ICI+radiation: specific specific abscopal effect local RT from specific specific anti-CTLA-4 IO/RT synergy from specific specific ICI+targeted therapy: specific specific pembrolizumab+lenvatinib RCC from specific specific durvalumab+olaparib BRCA1/2 from specific specific ICI+LAG-3: specific specific relatlimab+nivolumab RELATIVITY-047 melanoma from specific specific PFS 10.12 vs. 4.63 months HR 0.75 FDA 2022).

CAR-T chimeric antigen receptor construct and co-stimulatory domain innovations; bispecific T-cell engager BiTE and CD3 redirecting antibody innovations; and novel immune checkpoint target LAG-3 TIGIT TIM-3 and innate immune modulator innovations represent additional immunotherapy patent domains: CAR-T PATENTS: CARL JUNE/UPENN; NOVARTIS; KITE/GILEAD; BRISTOL MYERS SQUIBB; ALLOGENE: specific CAR-T innovations (specific specific 2nd generation CAR: specific specific VL-VH scFv antigen binding from specific specific CD8α/CD28 hinge transmembrane from specific specific 4-1BB CD137 co-stimulatory Carl June/UPenn from specific specific CD3ζ signaling domain from specific specific CAR expression: specific specific lentiviral pMSGV MSCV vector from specific specific 10⁶-10⁸ CAR-T cells/kg from specific specific Kymriah tisagenlecleucel: specific specific CD19 ALL B-NHL pediatric from specific specific 73% CR rate pediatric FDA 2017 from specific specific Yescarta axicabtagene: specific specific CD28 co-stimulatory vs. 4-1BB from specific specific CD19 LBCL 82% ORR FDA 2017 from specific specific CRISPR-edited allogeneic: specific specific TRC TRAC knockout from specific specific CD52 lymphodepletion resistance from specific specific TCR KO LAG-3 upregulation from specific specific Allogene ALLO-501A from specific specific armored CAR: specific specific IL-12 IL-15 IL-21 autocrine from specific specific CAR19+22 dual target); BISPECIFIC ANTIBODY PATENTS: AMGEN; GENENTECH; ABBVIE; JANSSEN; MERUS: specific bispecific innovations (specific specific BiTE bispecific T-cell engager: specific specific CD3ε×tumor antigen from specific specific Blinatumomab CD19×CD3 ALL from specific specific 3 μg/m²/day continuous infusion from specific specific 39% CR r/r B-ALL FDA 2014 from specific specific half-life: specific specific single chain <1 day from specific specific IgG-like Fc: specific specific CrossMab KiH knobs-into-holes from specific specific DART diabody alternate VH/VL from specific specific 14 days half-life from specific specific catumaxomab anti-EpCAM×anti-CD3 from specific specific solid tumor T-cell redirect from specific specific HER2×CD3: specific specific zanidatamab ZW25 HER2+ from specific specific PD-L1×CD3 specific specific linker engineering); NOVEL TARGET PATENTS: BMS; AZ; MERCK; INCYTE; AGENUS; ARCUS: specific novel target innovations (specific specific LAG-3: specific specific relatlimab BMS-986016 HR 0.75 FDA 2022 from specific specific LAG-3 blocks MHC II from specific specific TIGIT: specific specific tiragolumab 2020 AZ SKYSCRAPER from specific specific CD155 CD112 CD226 axis from specific specific TIM-3: specific specific cobolimab TSR-022 sabatolimab Novartis from specific specific VISTA V-domain Ig from specific specific STING: specific specific ADU-S100 cGAS-STING innate immune from specific specific ADUS100 intratumoral 0.1-1 mg).

Immunotherapy checkpoint startup IP strategy must navigate BMS (2,000+) and Merck (1,000+) anti-PD-1 antibody IP and Roche (1,500+) anti-PD-L1 IP; understand that foundational PD-1 antibody composition claims are held by BMS/Ono and pembrolizumab claims by Merck; identify whitespace in novel checkpoint targets (LAG-3, TIGIT, TIM-3, VISTA), combination therapies, next-generation tumor-infiltrating lymphocyte TIL therapies, and bispecific antibodies — while understanding that the checkpoint inhibitor market exceeds $25B/yr and litigation between BMS and Merck over anti-PD-1 IP is ongoing: IMMUNOTHERAPY CHECKPOINT STARTUP IP STRATEGY: UNDERSTAND THE CHECKPOINT INHIBITOR PATENT LANDSCAPE — BMS AND MERCK HOLD BROAD ANTI-PD-1 AND COMPANION DIAGNOSTIC IP: BMS (Opdivo) and Merck (Keytruda) anti-PD-1 antibody composition claims cover the primary target — new entrants must either design around these claims (non-overlapping epitopes, bispecific configurations) or license; NOVEL CHECKPOINT TARGETS LAG-3 TIGIT TIM-3 ARE HIGHEST-VALUE LEAST-CONSOLIDATED IP DOMAINS: After LAG-3 FDA approval (RELATIVITY-047 2022) and multiple TIGIT Phase III trials (Merck, AZ, Roche), second-generation checkpoint targets represent the most commercially active new IP territory with less consolidated competition vs. PD-1/CTLA-4; BISPECIFIC ANTIBODIES COMBINING TWO CHECKPOINT TARGETS IN ONE MOLECULE ARE PATENT-VIABLE: Bispecific checkpoint inhibitors (anti-PD-1×anti-LAG-3, anti-PD-L1×anti-TGFβ) represent a distinct molecule class from monospecific antibodies — novel bispecific formats (CrossMab, DART, tandem scFv) and novel target combinations are patentable; WHEN TO PATENT IN IMMUNOTHERAPY CHECKPOINT: NOVEL ANTIBODY WITH MEASURED CLINICAL ACTIVITY: specific novel checkpoint antibody or combination (specific specific target antigen + specific specific antibody format + specific specific indication) with specific measured performance (specific specific ORR % + specific specific CR % + specific specific PFS months HR + specific specific OS months HR at specific specific patient population + specific specific biomarker companion diagnostic threshold + specific specific PD-L1 TPS or TMB mut/Mb for patient selection) vs. specific specific BMS Opdivo or Merck Keytruda pivotal trial baseline — measured ORR, PFS, and OS with biomarker enrichment vs. SOC checkpoint inhibitor baseline is the critical immuno-oncology IP metric; KEY FTO CHECKLIST: BMS nivolumab IgG4 S228P PD-1 80 km 2 mg/kg 480 mg Q4W CheckMate 066 72.9% 1-yr OS; ipilimumab IgG1 CTLA-4 3 mg/kg 11.2 months CheckMate 001; nivo+ipi 3+1 57.6% 5-yr CheckMate 067; Merck pembrolizumab IgG4 200 mg Q3W TMB-H 10 mut/Mb MSI-H dMMR 22C3 TPS 50% 40+ FDA approvals; AZ durvalumab anti-PD-L1 PACIFIC stage III; Roche atezolizumab IgG1 Fc null; relatlimab LAG-3 RELATIVITY-047 PFS HR 0.75 FDA 2022; bispecific cadonilimab AK104 PD-1×CTLA-4; blinatumomab CD19×CD3 3 μg/m²/day 39% CR; CAR-T CD19 4-1BB CD3ζ tisagenlecleucel 73% CR lentiviral; CRISPR allogeneic TRAC CD52 KO.